Source:http://linkedlifedata.com/resource/pubmed/id/21155831
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2011-6-10
|
pubmed:abstractText |
Storage of cell-containing blood components such as platelet concentrates (PCs) and red blood cells (RBCs) results in generation of biologically active compounds, many of which may be associated with adverse transfusion events. Priming of the neutrophil oxidase activity is a common characteristic of many of the biologically active compounds found in stored blood. We evaluated the priming activity of pathogen reduction technology (PRT)-treated PCs stored in plasma or platelet additive solution (PAS) and PRT-treated RBCs.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1537-2995
|
pubmed:author | |
pubmed:copyrightInfo |
© 2010 American Association of Blood Banks.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
51
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1220-7
|
pubmed:meshHeading | |
pubmed:year |
2011
|
pubmed:articleTitle |
Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions.
|
pubmed:affiliation |
Bonfils Blood Center and the Center for Cancer and Blood Disorders, The Children's Hospital, Denver, Colorado, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|